EE200000671A - Solid compositions comprising gamma-aminobutyric acid derivatives and a process for their preparation - Google Patents

Solid compositions comprising gamma-aminobutyric acid derivatives and a process for their preparation

Info

Publication number
EE200000671A
EE200000671A EEP200000671A EEP200000671A EE200000671A EE 200000671 A EE200000671 A EE 200000671A EE P200000671 A EEP200000671 A EE P200000671A EE P200000671 A EEP200000671 A EE P200000671A EE 200000671 A EE200000671 A EE 200000671A
Authority
EE
Estonia
Prior art keywords
gamma
preparation
acid derivatives
aminobutyric acid
solid compositions
Prior art date
Application number
EEP200000671A
Other languages
Estonian (et)
Inventor
Aomatsu Akira
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200000671(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority claimed from PCT/US1999/010186 external-priority patent/WO1999059572A1/en
Publication of EE200000671A publication Critical patent/EE200000671A/en
Publication of EE05530B1 publication Critical patent/EE05530B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Arrangement Of Transmissions (AREA)
  • Body Structure For Vehicles (AREA)

Abstract

1. Technical Result Increase in efficiency of neuropathologic diseases treatment. 2. Essence A pharmaceutical composition containing as an active compound 4-amino-3-substituted-butanoic acid derivative of the general formula NH2 CH2 - C - CH2 COOH R1 R2 wherein the values R1 and R2, have the values indicated in the description, humectants in pharmaceutically effective amount and pharmaceutically acceptable auxiliaries. The composition is obtained by mixing the mentioned compound, humectant and pharmaceutically acceptable auxiliaries. 3. Field of Application Medicine. Tables: 10
EEP200000671A 1998-05-15 1999-05-10 Solid compositions comprising gamma-amino acid derivatives and a process for their preparation EE05530B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13312298A JP3761324B2 (en) 1998-05-15 1998-05-15 Passenger rice transplanter
PCT/US1999/010186 WO1999059572A1 (en) 1998-05-15 1999-05-10 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same

Publications (2)

Publication Number Publication Date
EE200000671A true EE200000671A (en) 2002-04-15
EE05530B1 EE05530B1 (en) 2012-04-16

Family

ID=15097314

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000671A EE05530B1 (en) 1998-05-15 1999-05-10 Solid compositions comprising gamma-amino acid derivatives and a process for their preparation

Country Status (16)

Country Link
JP (1) JP3761324B2 (en)
CN (1) CN1171587C (en)
AT (1) ATE407668T1 (en)
CA (1) CA2325045C (en)
CY (1) CY1108488T1 (en)
DE (1) DE69939532D1 (en)
DK (1) DK1077691T3 (en)
EA (1) EA006553B1 (en)
EE (1) EE05530B1 (en)
EG (1) EG26287A (en)
ES (1) ES2312208T3 (en)
GE (1) GEP20032987B (en)
IL (2) IL139202A0 (en)
NZ (1) NZ507162A (en)
PT (1) PT1077691E (en)
UA (1) UA76398C2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4904636B2 (en) * 2001-05-29 2012-03-28 井関農機株式会社 Tractor frame
JP5047022B2 (en) * 2008-03-24 2012-10-10 ヤンマー株式会社 Upper and lower split engine storage package connection structure
WO2013008182A1 (en) * 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015519333A (en) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of neurological disorders
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US20150087674A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
CN104352476A (en) * 2014-10-21 2015-02-18 齐宏 Gabapentin capsule and preparation method thereof
JP6564868B2 (en) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Three component salts of fumaric acid monomethyl ester and piperazine or ethylenediamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain

Also Published As

Publication number Publication date
CA2325045C (en) 2005-05-03
CN1171587C (en) 2004-10-20
EA200001154A1 (en) 2001-06-25
UA76398C2 (en) 2006-08-15
EA006553B1 (en) 2006-02-24
GEP20032987B (en) 2003-06-25
CY1108488T1 (en) 2014-04-09
ATE407668T1 (en) 2008-09-15
PT1077691E (en) 2008-11-04
CN1300213A (en) 2001-06-20
DK1077691T3 (en) 2008-10-27
IL139202A0 (en) 2001-11-25
EG26287A (en) 2013-06-12
JPH11318133A (en) 1999-11-24
EE05530B1 (en) 2012-04-16
JP3761324B2 (en) 2006-03-29
DE69939532D1 (en) 2008-10-23
ES2312208T3 (en) 2009-02-16
CA2325045A1 (en) 1999-11-25
NZ507162A (en) 2003-11-28
IL139202A (en) 2014-12-31

Similar Documents

Publication Publication Date Title
EE200000671A (en) Solid compositions comprising gamma-aminobutyric acid derivatives and a process for their preparation
BR9510168A (en) Polyamino acid compound composition unit dosage form and method for preparing a composition
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
ES2295609T3 (en) TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN.
GEP20043237B (en) Pyrazoline Derivatives, Method for Their Preparation and Compositions Containing Them for Treatment of Diseases Mediated by Cyclooxygenase-2
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
DE69815750D1 (en) Process for the preparation of ascorbic acid derivatives
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
RU94046044A (en) NEW 7β-SUBSTITUTED 4-AZA-5a-CHOLESTAN-ONES AS INHIBITORS OF 5a-REDUCTASE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD OF ITS PREPARING
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
ATE84045T1 (en) INHIBITING SUBSTANCES ENKEPHALINASE-B THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.
DE60022895D1 (en) PDGF-RECEPTOR-KINASE-INHIBITABLE COMPOUNDS, THE PREPARATION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
RU94038256A (en) Derivatives of pyrazolopyrimidine, method of their synthesis, pharmaceutical compositions based on thereof
JPH0256413A (en) Method and agent for preventing contamination of tooth
TR199801229T2 (en) "Thiol derivatives with metalopeptidase inhibition activity"
UA42733C2 (en) Bis-naphthalimide derivatives and pharmaceutically acceptable acid addition salts thereof, pharmaceutical composition containing them showing cytotoxic activity
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
HUT77135A (en) Process for preparing pharmaceutical compositions for preventing and treating ry type i allergic diseases
EP0996437B1 (en) Semisolid pharmaceutical formulation containing dexketoprofen trometamol
RU94031479A (en) New application of amino acid derivatives, treatment method, pharmaceutical composition
HU903092D0 (en) Process for the preparation of buten-carboxylic acid derivatives and pharmaceutical compositions containing such compounds

Legal Events

Date Code Title Description
HC1A Change of owner name